ENDOLOGIX INCO. sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive
The independent financial analyst theScreener just awarded an improved star rating to ENDOLOGIX INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date May 26, 2020, the closing price was USD 0.87 and its target price was estimated at USD 0.41.Endologix develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. The company's products are designed for the endovascular treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: endovascular aneurysm repair (EVAR); or endovascular aneurysm sealing (EVAS), the company's solution for sealing the aneurysm sac while maintaining blood flow. The company's EVAR products include the AFX? Endovascular AAA System, the VELA? Proximal Endograft, and the Ovation? Abdominal Stent Graft System. The company's EVAS product is the Nellix? Endovascular Aneurysm Sealing System.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.